---
title: "Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283180866.md"
description: "Genmab A/S has updated its Articles of Association to enhance capital-raising and employee incentive flexibility. The company filed a Form 6-K with the SEC, allowing the board to issue new shares, employee warrants, and convertible debt until March 2029 or 2030. The share capital remains at DKK 62,350,721. This change aims to support future financing and expansion without frequent shareholder meetings. Analysts rate GMAB stock as a Buy with a $40.00 price target, while Spark's AI Analyst gives it a Neutral score due to strong financial performance but concerns over leverage and earnings quality."
datetime: "2026-04-17T16:50:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283180866.md)
  - [en](https://longbridge.com/en/news/283180866.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283180866.md)
---

# Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An announcement from Genmab ( (GMAB) ) is now available.

Genmab A/S filed a Form 6-K with the U.S. Securities and Exchange Commission dated April 17, 2026, publishing an updated English translation of its Articles of Association as of March 19, 2026. The filing formalizes existing authorizations for the board to issue new shares, employee warrants and convertible debt, clarifies the company’s group language as English, and maintains Copenhagen as its registered office.

The revised Articles keep the share capital at DKK 62,350,721 while allowing the board, until March 2029 or 2030 depending on the program, to raise additional equity without or with pre-emption rights, grant employee warrants and issue convertible instruments up to specified nominal limits. These measures give Genmab added flexibility in capital raising and employee incentive structures, potentially supporting future financing and expansion without needing frequent shareholder meetings.

The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

**Spark’s Take on GMAB Stock**

According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.

The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.

To see Spark’s full report on GMAB stock, click here.

**More about Genmab**

Genmab A/S is a Denmark-based biotechnology company focused on medical research, development, production and sale of pharmaceutical products. The company operates through a share capital structure denominated in Danish kroner and uses equity, warrants and convertible instruments to finance growth and incentivize employees.

**Average Trading Volume:** 1,641,098

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $17.9B

For an in-depth examination of GMAB stock, go to TipRanks’ Overview page.

### Related Stocks

- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)

## Related News & Research

- [Genmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLY](https://longbridge.com/en/news/285581260.md)
- [Genmab Discloses Orbis as New 5% Major Shareholder](https://longbridge.com/en/news/281419643.md)
- [First Bancorp Updates Corporate Bylaws and Governance Framework](https://longbridge.com/en/news/284914362.md)
- [Alltronics Calls EGM to Approve Overhaul of Corporate Constitution](https://longbridge.com/en/news/285061816.md)
- [Genmab Updates Articles of Association, Expands Capital Issuance Flexibility](https://longbridge.com/en/news/280180559.md)